Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT02201420
Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT
Overview
The purpose of this study (NAV3-12) is to determine the dissemination and localization of Tc 99m tilmanocept by SPECT and SPECT/CT imaging in subjects with confirmed cutaneous KS. This is a single center, open-label, within-subject study.
Sponsor
Avid Radiopharmaceuticals
Phase
Phase 2
Contacts
Bonnie C Abbruzzese, MS, RD, CCRA (STUDY_DIRECTOR)
ClinicalTrials.gov
NCT02201420Drug / Compound
tilmanocept
Isotope(s):
TECHNETIUM-99m
Radioisotope: Tc-99m
Theranostic Role: SPECT Imaging
T1/2 (Half-Life): 6 Hours
Decay Mode: GAMMA
Energy: 140 keV (89.1%)
Range: N/A
Decay Daughters: Tc99
Status: FDA Approval: First in 1980’s
Target(s):
- Mannose Receptor (CD206/MRC1)
Ligand Class: Small Molecules
Chelator: DTPA
Eligibility
Inclusion
- The subject has a marker lesion with a confirmed diagnosis of KS (CD 206-expressing cutaneous KS) via punch biopsy. The location of the marker KS lesion will be limited to locations on the extremities: from the shoulder to the metacarpal region or from the groin to the metatarsal region.
- The subject has a KS stage of T(0), I(0), S(0).
- The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of Grade 0 to 2.
- The subject has a marker KS lesion that is ≥ 1cm in diameter.
Exclusion
- The subject has known sensitivity to dextran.
- The subject is pregnant or lactating.
- The subject has had prior chemotherapy, immunotherapy, or radiation therapy to the local KS site or regional lymphatic system within one year of enrollment.
- The subject has undergone node basin surgery of any type or radiation to the nodal basin(s) potentially draining the marker KS lesion.
Share your feedback
Help us improve your experience